Metformin treatment rescues CD8⁺ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD.

ABSTRACT:

Background & aims

Non-alcoholic steatohepatitis (NASH) represents the fastest growing underlying cause of hepatocellular carcinoma (HCC) and has been shown to impact immune effector cell function. The standard of care for the treatment of advanced HCC is immune checkpoint inhibitor (ICI) therapy, yet NASH may negatively affect the efficacy of ICI therapy in HCC. The immunologic mechanisms underlying the impact of NASH on ICI therapy remain unclear.

Methods

Herein, using multiple murine NASH models, we analysed the influence of NASH on the CD8⁺ T-cell-dependent anti-PD-1 responses against liver cancer. We characterised CD8⁺ T cells' transcriptomic, functional, and motility changes in mice receiving a normal diet (ND) or a NASH diet.

Results

NASH b

SUBMITTER: Wabitsch S 

PROVIDER: S-EPMC9391315 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature